Adriana Albini

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/7000743/publications.pdf

Version: 2024-02-01

239 papers	16,637 citations	13332 70 h-index	21843 118 g-index
243 all docs	243 docs citations	243 times ranked	24853 citing authors

#	Article	IF	Citations
1	An Olive Oil Mill Wastewater Extract Improves Chemotherapeutic Activity Against Breast Cancer Cells While Protecting From Cardiotoxicity. Frontiers in Cardiovascular Medicine, 2022, 9, 867867.	1.1	7
2	Decidual-Like NK Cell Polarization: From Cancer Killing to Cancer Nurturing. Cancer Discovery, 2021, 11, 28-33.	7.7	19
3	Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy. Cells, 2021, 10, 231.	1.8	34
4	Insights into phenolic compounds from microalgae: structural variety and complex beneficial activities from health to nutraceutics. Critical Reviews in Biotechnology, 2021, 41, 155-171.	5.1	60
5	Case Report: An Unusual Case of Biventricular Thrombosis in a COVID-19 Patient With Ischemic Dilated Cardiomyopathy: Assessment of Mass Mobility and Embolic Risk by Tissue Doppler Imaging. Frontiers in Cardiovascular Medicine, 2021, 8, 694542.	1.1	9
6	A Polyphenol-Rich Extract of Olive Mill Wastewater Enhances Cancer Chemotherapy Effects, While Mitigating Cardiac Toxicity. Frontiers in Pharmacology, 2021, 12, 694762.	1.6	13
7	Preliminary Evidence for IL-10-Induced ACE2 mRNA Expression in Lung-Derived and Endothelial Cells: Implications for SARS-Cov-2 ARDS Pathogenesis. Frontiers in Immunology, 2021, 12, 718136.	2.2	18
8	A Case of Acute Pericarditis After COVID-19 Vaccination. Frontiers in Allergy, 2021, 2, 733466.	1.2	0
9	TIMP1 and TIMP2 Downregulate TGFÎ² Induced Decidual-like Phenotype in Natural Killer Cells. Cancers, 2021, 13, 4955.	1.7	15
10	Two Novel Ceramide-Like Molecules and miR-5100 Levels as Biomarkers Improve Prediction of Prostate Cancer in Gray-Zone PSA. Frontiers in Oncology, 2021, 11, 769158.	1.3	7
11	The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-based antihypertensive therapiesâ€"reply. Internal and Emergency Medicine, 2020, 15, 1583-1584.	1.0	21
12	Cardiovascular Active Peptides of Marine Origin with ACE Inhibitory Activities: Potential Role as Anti-Hypertensive Drugs and in Prevention of SARS-CoV-2 Infection. International Journal of Molecular Sciences, 2020, 21, 8364.	1.8	14
13	PKHhigh/CD133+/CD24âˆ' Renal Stem-Like Cells Isolated from Human Nephrospheres Exhibit In Vitro Multipotency. Cells, 2020, 9, 1805.	1.8	4
14	COVID-19 and Obesity: Dangerous Liaisons. Journal of Clinical Medicine, 2020, 9, 2511.	1.0	107
15	The SARS-CoV-2 receptor, ACE-2, is expressed on many different cell types: implications for ACE-inhibitor- and angiotensin II receptor blocker-basedÂcardiovascular therapies. Internal and Emergency Medicine, 2020, 15, 759-766.	1.0	118
16	Marine Algal Antioxidants as Potential Vectors for Controlling Viral Diseases. Antioxidants, 2020, 9, 392.	2.2	41
17	Speckle-Tracking Echocardiography for Cardioncological Evaluation in Bevacizumab-Treated Colorectal Cancer Patients. Cardiovascular Toxicology, 2020, 20, 581-592.	1.1	9
18	Endometrial Cancer Immune Escape Mechanisms: Let Us Learn From the Fetalâ€"Maternal Interface. Frontiers in Oncology, 2020, 10, 156.	1.3	24

#	Article	IF	Citations
19	An Extract of Olive Mill Wastewater Downregulates Growth, Adhesion and Invasion Pathways in Lung Cancer Cells: Involvement of CXCR4. Nutrients, 2020, 12, 903.	1.7	15
20	Prostate Cancer Peripheral Blood NK Cells Show Enhanced CD9, CD49a, CXCR4, CXCL8, MMP-9 Production and Secrete Monocyte-Recruiting and Polarizing Factors. Frontiers in Immunology, 2020, 11, 586126.	2.2	40
21	Nutraceuticals and "Repurposed" Drugs of Phytochemical Origin in Prevention and Interception of Chronic Degenerative Diseases and Cancer. Current Medicinal Chemistry, 2019, 26, 973-987.	1.2	19
22	Microalgal Derivatives as Potential Nutraceutical and Food Supplements for Human Health: A Focus on Cancer Prevention and Interception. Nutrients, 2019, 11, 1226.	1.7	168
23	Myeloid Derived Suppressor Cells Interactions With Natural Killer Cells and Pro-angiogenic Activities: Roles in Tumor Progression. Frontiers in Immunology, 2019, 10, 771.	2.2	146
24	Acetyl-L-Carnitine downregulates invasion (CXCR4/CXCL12, MMP-9) and angiogenesis (VEGF, CXCL8) pathways in prostate cancer cells: rationale for prevention and interception strategies. Journal of Experimental and Clinical Cancer Research, 2019, 38, 464.	3.5	42
25	Innate Immune Response Regulation by the Human RNASET2 Tumor Suppressor Gene. Frontiers in Immunology, 2019, 10, 2587.	2.2	22
26	Downregulation of Pro-Inflammatory and Pro-Angiogenic Pathways in Prostate Cancer Cells by a Polyphenol-Rich Extract from Olive Mill Wastewater. International Journal of Molecular Sciences, 2019, 20, 307.	1.8	36
27	Prophylaxis of Non-communicable Diseases: Why Fruits and Vegetables may be Better Chemopreventive Agents than Dietary Supplements Based on Isolated Phytochemicals?. Current Pharmaceutical Design, 2019, 25, 1847-1860.	0.9	21
28	Acetyl- l -carnitine is an anti-angiogenic agent targeting the VEGFR2 and CXCR4 pathways. Cancer Letters, 2018, 429, 100-116.	3.2	24
29	What the oncologist can learn from diabetes studies: Epidemiology, prevention, management, cure. Diabetes Research and Clinical Practice, 2018, 143, 364-368.	1.1	1
30	Cancer chemoprevention revisited: Cytochrome P450 family 1B1 as a target in the tumor and the microenvironment. Cancer Treatment Reviews, 2018, 63, 1-18.	3.4	78
31	Pathologic Grading of Malignant Pleural Mesothelioma: An Evidence-Based Proposal. Journal of Thoracic Oncology, 2018, 13, 1750-1761.	0.5	27
32	Natural Killer Cells from Malignant Pleural Effusion Are Endowed with a Decidual-Like Proangiogenic Polarization. Journal of Immunology Research, 2018, 2018, 1-18.	0.9	43
33	Angiogenin and the MMP9â€TIMP2 axis are upâ€regulated in proangiogenic, decidual NKâ€like cells from patients with colorectal cancer. FASEB Journal, 2018, 32, 5365-5377.	0.2	91
34	Serum Steroid Ratio Profiles in Prostate Cancer: A New Diagnostic Tool Toward a Personalized Medicine Approach. Frontiers in Endocrinology, 2018, 9, 110.	1.5	10
35	Contribution to Tumor Angiogenesis From Innate Immune Cells Within the Tumor Microenvironment: Implications for Immunotherapy. Frontiers in Immunology, 2018, 9, 527.	2.2	297
36	Synthesis and antiangiogenic activity study of new hop chalcone Xanthohumol analogues. European Journal of Medicinal Chemistry, 2017, 138, 890-899.	2.6	24

#	Article	IF	Citations
37	SANIST: optimization of a technology for compound identification based on the European Union directive with applications in forensic, pharmaceutical and food analyses. Journal of Mass Spectrometry, 2017, 52, 16-21.	0.7	17
38	Nutrigenomics of extraâ€virgin olive oil: A review. BioFactors, 2017, 43, 17-41.	2.6	147
39	Therapeutic potential of the metabolic modulator phenformin in targeting the stem cell compartment in melanoma. Oncotarget, 2017, 8, 6914-6928.	0.8	38
40	TAT Protein of HIV. , 2017, , 4455-4458.		0
41	Systemic distribution of single-walled carbon nanotubes in a novel model: alteration of biochemical parameters, metabolic functions, liver accumulation, and inflammation in vivo. International Journal of Nanomedicine, 2016, Volume 11, 4299-4316.	3.3	43
42	Hop derived flavonoid xanthohumol inhibits endothelial cell functions via AMPK activation. Oncotarget, 2016, 7, 59917-59931.	0.8	28
43	Fenretinide (4-HPR) Targets Caspase-9, ERK 1/2 and the Wnt3a/β2-Catenin Pathway in Medulloblastoma Cells and Medulloblastoma Cell Spheroids. PLoS ONE, 2016, 11, e0154111.	1.1	24
44	A highly invasive subpopulation of MDA-MB-231 breast cancer cells shows accelerated growth, differential chemoresistance, features of apocrine tumors and reduced tumorigenicityin vivo. Oncotarget, 2016, 7, 68803-68820.	0.8	30
45	Cancer Prevention and Interception: A New Era for Chemopreventive Approaches. Clinical Cancer Research, 2016, 22, 4322-4327.	3.2	45
46	Potential chemopreventive activities of a polyphenol rich purified extract from olive mill wastewater on colon cancer cells. Journal of Functional Foods, 2016, 27, 236-248.	1.6	39
47	Extracellular Matrix Invasion in Metastases and Angiogenesis: Commentary on the Matrigel â€œChemoinvasion Assayâ€. Cancer Research, 2016, 76, 4595-4597.	0.4	22
48	Aspirin and atenolol enhance metformin activity against breast cancer by targeting both neoplastic and microenvironment cells. Scientific Reports, 2016, 6, 18673.	1.6	46
49	Environmental impact of multi-wall carbon nanotubes in a novel model of exposure: systemic distribution, macrophage accumulation, and amyloid deposition. International Journal of Nanomedicine, 2015, 10, 6133.	3.3	28
50	Preliminary Evidence on the Diagnostic and Molecular Role of Circulating Soluble EGFR in Non-Small Cell Lung Cancer. International Journal of Molecular Sciences, 2015, 16, 19612-19630.	1.8	21
51	Effects of 5-Fluorouracil on Morphology, Cell Cycle, Proliferation, Apoptosis, Autophagy and ROS Production in Endothelial Cells and Cardiomyocytes. PLoS ONE, 2015, 10, e0115686.	1.1	217
52	Biomarkers of cancer angioprevention for clinical studies. Ecancermedicalscience, 2015, 9, 600.	0.6	6
53	SANIST: a rapid mass spectrometric SACI/ESI data acquisition and elaboration platform for verifying potential candidate biomarkers. Rapid Communications in Mass Spectrometry, 2015, 29, 1703-1710.	0.7	18
54	N-O-Isopropyl Sulfonamido-Based Hydroxamates as Matrix Metalloproteinase Inhibitors: Hit Selection and in Vivo Antiangiogenic Activity. Journal of Medicinal Chemistry, 2015, 58, 7224-7240.	2.9	54

#	Article	IF	Citations
55	Cancer stem cells and the tumor microenvironment: interplay in tumor heterogeneity. Connective Tissue Research, 2015, 56, 414-425.	1.1	123
56	Strategies to Prevent â€œBad Luckâ€• in Cancer. Journal of the National Cancer Institute, 2015, 107, djv213.	3.0	30
57	The biguanides metformin and phenformin inhibit angiogenesis, local and metastatic growth of breast cancer by targeting both neoplastic and microenvironment cells. International Journal of Cancer, 2015, 136, E534-44.	2.3	119
58	A PSA-guided approach for a better diagnosis of prostatic adenocarcinoma based on MALDI profiling and peptide identification. Clinica Chimica Acta, 2015, 439, 42-49.	0.5	14
59	TAT Protein of HIV. , 2015, , 1-4.		0
60	Glycogen Synthase Kinase 3 Regulates Cell Death and Survival Signaling in Tumor Cells under Redox Stress. Neoplasia, 2014, 16, 710-722.	2.3	19
61	Orchestration of Angiogenesis by Immune Cells. Frontiers in Oncology, 2014, 4, 131.	1.3	99
62	Paradoxic effects of metformin on endothelial cells and angiogenesis. Carcinogenesis, 2014, 35, 1055-1066.	1.3	118
63	Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel. Cancer and Metastasis Reviews, 2014, 33, 657-671.	2.7	49
64	Inflammatory Angiogenesis and the Tumor Microenvironment as Targets for Cancer Therapy and Prevention. Cancer Treatment and Research, 2014, 159, 401-426.	0.2	33
65	A Think Tank of TINK/TANKs: Tumor-Infiltrating/Tumor-Associated Natural Killer Cells in Tumor Progression and Angiogenesis. Journal of the National Cancer Institute, 2014, 106, 1-13.	3.0	649
66	Drink your prevention: beverages with cancer preventive phytochemicals. Polish Archives of Internal Medicine, 2014, 124, 713-722.	0.3	22
67	Fluoropyrimidine toxicity in patients with dihydropyrimidine dehydrogenase splice site variant: the need for further revision of dose and schedule. Internal and Emergency Medicine, 2013, 8, 417-423.	1.0	15
68	The Proangiogenic Phenotype of Natural Killer Cells in Patients with Non-Small Cell Lung Cancer. Neoplasia, 2013, 15, 133-IN7.	2.3	196
69	Surfaceâ€activated chemical ionizationâ€“electrospray mass spectrometry in the analysis of urinary thiodiglycolic acid. Rapid Communications in Mass Spectrometry, 2013, 27, 476-480.	0.7	2
70	Angiopoietin2 and Tie2: Tied to Lymphangiogenesis and Lung Metastasis. New Perspectives in Antimetastatic Antiangiogenic Therapy. Journal of the National Cancer Institute, 2012, 104, 429-431.	3.0	16
71	Cancer prevention by targeting angiogenesis. Nature Reviews Clinical Oncology, 2012, 9, 498-509.	12.5	264
72	Renal dysfunction and increased risk of cardiotoxicity with trastuzumab therapy: a new challenge in cardio-oncology. Internal and Emergency Medicine, 2012, 7, 399-401.	1.0	11

#	Article	IF	Citations
73	Effects of Diet-Derived Molecules on the Tumor Microenvironment. Current Angiogenesis, 2012, 1, 206-214.	0.1	4
74	Surfaceâ€activated chemical ionizationâ€“electrospray ionization source improves biomarker discovery with mass spectrometry. Rapid Communications in Mass Spectrometry, 2012, 26, 1213-1218.	0.7	7
75	Bringing new players into the field: onco-pharmacovigilance in the era of cardio-oncology. Internal and Emergency Medicine, 2012, 7, 99-101.	1.0	12
76	An integrin-binding N-terminal peptide region of TIMP-2 retains potent angio-inhibitory and anti-tumorigenic activity in vivo. Peptides, 2011, 32, 1840-1848.	1.2	35
77	Diacylglycerol kinases are essential for hepatocyte growth factorâ€dependent proliferation and motility of Kaposiâ€™s sarcoma cells. Cancer Science, 2011, 102, 1329-1336.	1.7	23
78	Cancer Stem Cells and the Tumor Microenvironment: Soloists or Choral Singers. Current Pharmaceutical Biotechnology, 2011, 12, 171-181.	0.9	20
79	Cardio-oncology in targeting the HER receptor family: the puzzle of different cardiotoxicities of HER2 inhibitors. Future Cardiology, 2011, 7, 693-704.	0.5	43
80	Response: Re: Neurocognitive Functioning in Adult Survivors of Childhood Noncentral Nervous System Cancers. Journal of the National Cancer Institute, 2011, 103, 608-609.	3.0	2
81	The Angiogenic Switch: Role of Immune Cells. , 2011, , 57-75.		2
82	TAT Protein of HIV. , 2011, , 3611-3613.		0
83	Interactions of single-wall carbon nanotubes with endothelial cells. Nanomedicine: Nanotechnology, Biology, and Medicine, 2010, 6, 277-288.	1.7	72
84	Functional genomics of endothelial cells treated with anti-angiogenic or angiopreventive drugs. Clinical and Experimental Metastasis, 2010, 27, 419-439.	1.7	15
85	Genomics of metastatic progression. Clinical and Experimental Metastasis, 2010, 27, 453-453.	1.7	0
86	The â€˜chemoinvasionâ€™ assay, 25 years and still going strong: the use of reconstituted basement membranes to study cell invasion and angiogenesis. Current Opinion in Cell Biology, 2010, 22, 677-689.	2.6	65
87	Angioprevention with fenretinide: Targeting angiogenesis in prevention and therapeutic strategies. Critical Reviews in Oncology/Hematology, 2010, 75, 2-14.	2.0	39
88	Capecitabine in Breast Cancer: The Issue of Cardiotoxicity During Fluoropyrimidine Treatment. Breast Journal, 2010, 16, S45-S48.	0.4	25
89	Reference Profile Correlation Reveals Estrogen-like Trancriptional Activity of Curcumin. Cellular Physiology and Biochemistry, 2010, 26, 471-482.	1.1	73
90	Antiangiogenic and Antitumor Effects of Trypanosoma cruzi Calreticulin. PLoS Neglected Tropical Diseases, 2010, 4, e730.	1.3	60

#	Article	IF	Citations
91	The tumor microenvironment of colorectal cancer: stromal TLR-4 expression as a potential prognostic marker. Journal of Translational Medicine, 2010, 8, 112.	1.8	120
92	Cardiotoxicity of Anticancer Drugs: The Need for Cardio-Oncology and Cardio-Oncological Prevention. Journal of the National Cancer Institute, 2010, 102, 14-25.	3.0	658
93	Invasion and Metastasis. , 2010, , 213-228.		3
94	Anti-FGF2 approaches asÂaÂstrategy toÂcompensate resistance toÂanti-VEGF therapy: long-pentraxin 3Âas aÂnovel antiangiogenic FGF2-antagonist. European Cytokine Network, 2009, 20, 225-234.	1.1	76
95	Anti-angiogenic Activity of a Novel Class of Chemopreventive Compounds: Oleanic Acid Terpenoids. Recent Results in Cancer Research, 2009, 181, 209-212.	1.8	50
96	Metabolic regulation and redox activity as mechanisms for angioprevention by dietary phytochemicals. International Journal of Cancer, 2009, 125, 1997-2003.	2.3	64
97	Prediction of breast cancer metastasis by genomic profiling: where do we stand?. Clinical and Experimental Metastasis, 2009, 26, 547-558.	1.7	30
98	Mechanisms of Hyperforin as an anti-angiogenic angioprevention agent. European Journal of Cancer, 2009, 45, 1474-1484.	1.3	35
99	Angiostatin anti-angiogenesis requires IL-12: The innate immune system as a key target. Journal of Translational Medicine, 2009, 7, 5.	1.8	43
100	Systemic Sclerosis-Endothelial Cell Antiangiogenic Pentraxin 3 and Matrix Metalloprotease 12 Control Human Breast Cancer Tumor Vascularization and Development in Mice. Neoplasia, 2009, 11, 1106-1115.	2.3	32
101	Anti-angiogenic properties of Chemopreventive Drugs: Fenretinide as a Prototype.. Recent Results in Cancer Research, 2009, 181, 71-76.	1.8	19
102	Tumor microenvironment, a dangerous society leading to cancer metastasis. From mechanisms to therapy and prevention. Cancer and Metastasis Reviews, 2008, 27, 3-4.	2.7	11
103	Inflammation, inflammatory cells and angiogenesis: decisions and indecisions. Cancer and Metastasis Reviews, 2008, 27, 31-40.	2.7	230
104	Metastasis signatures: genes regulating tumorâ€“microenvironment interactions predict metastatic behavior. Cancer and Metastasis Reviews, 2008, 27, 75-83.	2.7	76
105	Natural and Synthetic Agents Targeting Inflammation and Angiogenesis for Chemoprevention of Prostate Cancer. Current Cancer Drug Targets, 2008, 8, 146-155.	0.8	27
106	Prevention and Treatment of Experimental Estrogen Receptorâ€“Negative Mammary Carcinogenesis by the Synthetic Triterpenoid CDDO-Methyl Ester and the Rexinoid LG100268. Clinical Cancer Research, 2008, 14, 4556-4563.	3.2	65
107	Glycogen Synthase Kinase 3Î² Regulates Cell Death Induced by Synthetic Triterpenoids. Cancer Research, 2008, 68, 6987-6996.	0.4	36
108	Antileukemia effects of xanthohumol in Bcr/Abl-transformed cells involve nuclear factor-ÂB and p53 modulation. Molecular Cancer Therapeutics, 2008, 7, 2692-2702.	1.9	73

#	Article	IF	Citations
109	Endothelial Cell Aging and Apoptosis in Prevention and Disease: E-Selectin Expression and Modulation As A Model. Current Pharmaceutical Design, 2008, 14, 221-225.	0.9	39
110	Vascular Endothelial Growth Factor Receptor-1 Contributes to Resistance to Antiâ€“Epidermal Growth Factor Receptor Drugs in Human Cancer Cells. Clinical Cancer Research, 2008, 14, 5069-5080.	3.2	139
111	Hyperforin Blocks Neutrophil Activation of Matrix Metalloproteinase-9, Motility and Recruitment, and Restrains Inflammation-Triggered Angiogenesis and Lung Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2007, 321, 492-500.	1.3	47
112	Identification of Genes Selectively Regulated by IFNs in Endothelial Cells. Journal of Immunology, 2007, 178, 1122-1135.	0.4	152
113	Antiangiogenic Activity of the MDM2 Antagonist Nutlin-3. Circulation Research, 2007, 100, 61-69.	2.0	124
114	Molecular Pathways for Cancer Angioprevention: Fig. 1.. Clinical Cancer Research, 2007, 13, 4320-4325.	3.2	48
115	Novel cell death pathways induced by N-(4-hydroxyphenyl)retinamide: therapeutic implications. Molecular Cancer Therapeutics, 2007, 6, 286-298.	1.9	23
116	The synthetic oleanane triterpenoid, CDDO-methyl ester, is a potent antiangiogenic agent. Molecular Cancer Therapeutics, 2007, 6, 3139-3146.	1.9	51
117	The Chemopreventive Polyphenol Curcumin Prevents Hematogenous Breast Cancer Metastases in Immunodeficient Mice. Cellular Physiology and Biochemistry, 2007, 19, 137-152.	1.1	187
118	Angiogenesis and Cancer Prevention: A Vision. , 2007, 174, 219-224.		70
119	Platforms and networks in triterpenoid pharmacology. Drug Development Research, 2007, 68, 174-182.	1.4	38
120	AKT/NFâ€ºB inhibitor xanthohumol targets cell growth and angiogenesis in hematologic malignancies. Cancer, 2007, 110, 2007-2011.	2.0	72
121	The chemoinvasion assay: a method to assess tumor and endothelial cell invasion and its modulation. Nature Protocols, 2007, 2, 504-511.	5.5	186
122	The tumour microenvironment as a target for chemoprevention. Nature Reviews Cancer, 2007, 7, 139-147.	12.8	700
123	Inhibition of a vascular ocular tumor growth by IL-12 gene transfer. Clinical and Experimental Metastasis, 2007, 24, 485-493.	1.7	6
124	Green tea polyphenol epigallocatechin-3-gallate inhibits the endothelin axis and downstream signaling pathways in ovarian carcinoma. Molecular Cancer Therapeutics, 2006, 5, 1483-1492.	1.9	73
125	Biological assays and genomic analysis reveal lipoic acid modulation of endothelial cell behavior and gene expression. Carcinogenesis, 2006, 28, 1008-1020.	1.3	28
126	The Akt inhibitor deguelin, is an angiopreventive agent also acting on the NF-ÂB pathway. Carcinogenesis, 2006, 28, 404-413.	1.3	59

#	Article	IF	Citations
127	Choking Hypoxia-Inducible Factor 1Î±: A Novel Mechanism for Connective Tissue Growth Factor Inhibition of Angiogenesis. Journal of the National Cancer Institute, 2006, 98, 946-948.	3.0	2
128	A New Tumor Suppressor Gene: Invasion, Metastasis, and Angiogenesis as Potential Key Targets. Journal of the National Cancer Institute, 2006, 98, 800-801.	3.0	6
129	Mechanisms of the antiangiogenic activity by the hop flavonoid xanthohumol: NFâ€ÎºB and Akt as targets. FASEB Journal, 2006, 20, 527-529.	0.2	166
130	Models of inflammatory processes in cancer. , 2006, , 83-102.		3
131	Molecular mechanisms of action of angiopreventive anti-oxidants on endothelial cells: Microarray gene expression analyses. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2005, 591, 198-211.	0.4	25
132	In vitro and in vivo tumor growth inhibition by a p16-mimicking peptide in p16INK4A-defective, pRb-positive human melanoma cells. Journal of Cellular Physiology, 2005, 202, 922-928.	2.0	8
133	N-i-Propoxy-N-biphenylsulfonylaminobutylhydroxamic acids as potent and selective inhibitors of MMP-2 and MT1-MMP. Bioorganic and Medicinal Chemistry Letters, 2005, 15, 1321-1326.	1.0	38
134	Transcriptional control of cell density dependent regulation of matrix metalloproteinase and TIMP expression in breast cancer cell lines. Thrombosis and Haemostasis, 2005, 93, 761-769.	1.8	12
135	Rescuing COX-2 Inhibitors From the Waste Bin. Journal of the National Cancer Institute, 2005, 97, 859-860.	3.0	13
136	Tumor Inflammatory Angiogenesis and Its Chemoprevention. Cancer Research, 2005, 65, 10637-10641.	0.4	184
137	The Transforming Growth Factor-Î² Family Members Bone Morphogenetic Protein-2 and Macrophage Inhibitory Cytokine-1 as Mediators of the Antiangiogenic Activity of N-(4-Hydroxyphenyl)Retinamide. Clinical Cancer Research, 2005, 11, 4610-4619.	3.2	72
138	The urokinase-type plasminogen activator, its receptor and u-PA inhibitor type-1 affect in vitro growth and invasion of Kaposi's sarcoma and capillary endothelial cells: role of HIV-Tat protein. International Journal of Oncology, 2005, 27, 223.	1.4	3
139	Cell density-dependent regulation of matrix metalloproteinase and TIMP expression in differently tumorigenic breast cancer cell lines. Experimental Cell Research, 2005, 305, 83-98.	1.2	38
140	CXCL1/Macrophage Inflammatory Protein-2-Induced Angiogenesis In Vivo Is Mediated by Neutrophil-Derived Vascular Endothelial Growth Factor-A. Journal of Immunology, 2004, 172, 5034-5040.	0.4	243
141	AAV-mediated gene transfer of tissue inhibitor of metalloproteinases-1 inhibits vascular tumor growth and angiogenesis in vivo. Cancer Gene Therapy, 2004, 11, 73-80.	2.2	58
142	Î±-Lipoic acid is effective in prevention and treatment of experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2004, 148, 146-153.	1.1	118
143	Inhibition of angiogenesis in vivo and growth of Kaposi's sarcoma xenograft tumors by the anti-malarial artesunate. Biochemical Pharmacology, 2004, 68, 2359-2366.	2.0	214
144	A WT1 expressing metastatic human kaposi sarcoma xenograft model. Pathology and Oncology Research, 2004, 10, 22-25.	0.9	4

#	Article	IF	Citations
145	Mechanisms of Inhibition of Tumor Angiogenesis and Vascular Tumor Growth by Epigallocatechin-3-Gallate. Clinical Cancer Research, 2004, 10, 4865-4873.	3.2	174
146	Antigenotoxic and Cancer Preventive Mechanisms of N-Acetyl-l-Cysteine. , 2004, , 37-67.		13
147	The "chemoinvasion assay": a tool to study tumor and endothelial cell invasion of basement membranes. International Journal of Developmental Biology, 2004, 48, 563-571.	0.3	76
148	The guanylate binding protein-1 GTPase controls the invasive and angiogenic capability of endothelial cells through inhibition of MMP-1 expression. EMBO Journal, 2003, 22, 3772-3782.	3.5	135
149	HIV Tat, its TARgets and the control of viral gene expression. FEMS Microbiology Letters, 2003, 220, 57-65.	0.7	96
150	Allele-specific patterns of the mouse parathyroid hormone-related protein: influences on cell adhesion and migration. Oncogene, 2003, 22, 7711-7715.	2.6	8
151	Endothelin Receptor Blockade Inhibits Molecular Effectors of Kaposi's Sarcoma Cell Invasion and Tumor Growth in Vivo. American Journal of Pathology, 2003, 163, 753-762.	1.9	55
152	Phenotypic and functional analysis of T cells homing into the CSF of subjects with inflammatory diseases of the CNS. Journal of Leukocyte Biology, 2003, 73, 584-590.	1.5	159
153	N-(4-Hydroxyphenyl)retinamide Inhibits Retinoblastoma Growth through Reactive Oxygen Species-Mediated Cell Death. Molecular Pharmacology, 2003, 63, 565-573.	1.0	42
154	Neutrophil Restraint by Green Tea: Inhibition of Inflammation, Associated Angiogenesis, and Pulmonary Fibrosis. Journal of Immunology, 2003, 170, 4335-4341.	0.4	311
155	Re: Microarray Studies Challenge Theories of Metastasis. Journal of the National Cancer Institute, 2003, 95, 829-829.	3.0	11
156	Angiostatin inhibits extracellular HIV-Tat-induced inflammatory angiogenesis. International Journal of Oncology, 2003, 22, 87.	1.4	5
157	Identification of Immunodominant Epitopes in Inactivated Tat-Vaccinated Healthy and HIV-1â€“Infected Volunteers. Journal of Acquired Immune Deficiency Syndromes (1999), 2003, 33, 47-55.	0.9	12
158	Neutrophils and Angiogenesis: Potential Initiators of the Angiogenic Cascade. , 2003, 83, 167-181.		44
159	Antiangiogenic activity of chemopreventive drugs. International Journal of Biological Markers, 2003, 18, 70-74.	0.7	26
160	Angiostatin inhibits extracellular HIV-Tat-induced inflammatory angiogenesis. International Journal of Oncology, 2003, 22, 87-91.	1.4	8
161	Inhibition of Kaposi's sarcoma in vivo by fenretinide. Clinical Cancer Research, 2003, 9, 6020-9.	3.2	35
162	Generation of Biologically Active Angiostatin Kringle 1â€“3 by Activated Human Neutrophils. Journal of Immunology, 2002, 168, 5798-5804.	0.4	125

#	Article	IF	Citations
163	Kaposis Sarcoma and Human Chorionic Gonadotropin: Mechanisms, Moieties and Mysteries. Biological Chemistry, 2002, 383, 1315-1320.	1.2	7
164	Inhibition of Tumor Angiogenesis by Angiostatin: From Recombinant Protein to Gene Therapy. Endothelium: Journal of Endothelial Cell Research, 2002, 9, 3-10.	1.7	37
165	Human Chorionic Gonadotropin Inhibits Kaposiâ€™s Sarcoma Associated Angiogenesis, Matrix Metalloprotease Activity, and Tumor Growth. Endocrinology, 2002, 143, 3114-3121.	1.4	20
166	Anti-Invasive Effects of Green Tea Polyphenol EpiGalloCatechin-3-Gallate (EGCG), a Natural Inhibitor of Metallo and Serine Proteases. Biological Chemistry, 2002, 383, 101-5.	1.2	94
167	HIV-1-Tat Protein Activates Phosphatidylinositol 3-Kinase/ AKT-dependent Survival Pathways in Kaposi's Sarcoma Cells. Journal of Biological Chemistry, 2002, 277, 25195-25202.	1.6	84
168	Neutrophils as a key cellular target for angiostatin: implications for regulation of angiogenesis and inflammation. FASEB Journal, 2002, 16, 1-17.	0.2	164
169	â€˜Angiopreventionâ€™: angiogenesis is a common and key target for cancer chemopreventive agents. FASEB Journal, 2002, 16, 2-14.	0.2	309
170	Role of the alpha3beta1 and alpha6beta4 integrins in tumor invasion. Clinical and Experimental Metastasis, 2002, 19, 217-223.	1.7	70
171	Tumors and inflammatory infiltrates: friends or foes?. Clinical and Experimental Metastasis, 2002, 19, 247-258.	1.7	201
172	Polyphenolic antioxidant (â€“)-epigallocatechin-3-gallate from green tea as a candidate anti-HIV agent. Aids, 2002, 16, 939-941.	1.0	116
173	Oxytocin is a growth factor for Kaposi's sarcoma cells: evidence of endocrine-immunological cross-talk. Cancer Research, 2002, 62, 2406-13.	0.4	20
174	HIV-1 Tat Causes Apoptotic Death and Calcium Homeostasis Alterations in Rat Neurons. Biochemical and Biophysical Research Communications, 2001, 288, 301-308.	1.0	128
175	Endothelin Receptor Blockade Inhibits Proliferation of Kaposiâ€™s Sarcoma Cells. American Journal of Pathology, 2001, 158, 841-847.	1.9	34
176	Rationale, Problems and Perspectives in Anti-angiogenic Therapy. Tumori, 2001, 87, 17-19.	0.6	0
177	Tumor gelatinases and invasion inhibited by the green tea flavanol epigallocatechin-3-gallate. Cancer, 2001, 91, 822-832.	2.0	291
178	Growth factor supplemented matrigel improves ectopic skeletal muscle formation?a cell therapy approach. Journal of Cellular Physiology, 2001, 186, 183-192.	2.0	47
179	Multiple points of intervention in the prevention of cancer and other mutation-related diseases. Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis, 2001, 480-481, 9-22.	0.4	89
180	HIV Type 1 Tat Protein Is a Survival Factor for Kaposi's Sarcoma and Endothelial Cells. AIDS Research and Human Retroviruses, 2001, 17, 965-976.	0.5	39

#	Article	IF	Citations
181	From the outside in: Extracellular activities of HIV tat. Advances in Pharmacology, 2000, 48, 229-250.	1.2	55
182	Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR. European Journal of Immunology, 2000, 30, 1120-1126.	1.6	29
183	The Î±3Î²1 integrin is associated with mammary carcinoma cell metastasis, invasion, and gelatinase B (mmp-9) activity. International Journal of Cancer, 2000, 87, 336-342.	2.3	245
184	Expression of functional tyrosine kinases on immortalized Kaposi's sarcoma cells. Journal of Cellular Physiology, 2000, 184, 246-254.	2.0	16
185	Tissue inhibitors of metalloproteases: regulation and biological activities. Clinical and Experimental Metastasis, 2000, 18, 111-120.	1.7	133
186	HIV-Tat dependent chemotaxis and invasion, key aspects of tat mediated pathogenesis. Clinical and Experimental Metastasis, 2000, 18, 533-538.	1.7	26
187	Bclâ€2 overexpression and hypoxia synergistically act to modulate vascular endothelial growth factor expression andin vivoangiogenesis in a breast carcinoma line. FASEB Journal, 2000, 14, 652-660.	0.2	115
188	The Combined Action of IL-15 and IL-12 Gene Transfer Can Induce Tumor Cell Rejection Without T and NK Cell Involvement. Journal of Immunology, 2000, 165, 3111-3118.	0.4	65
189	Human Immunodeficiency Virus Transactivator Protein (Tat) Stimulates Chemotaxis, Calcium Mobilization, and Activation of Human Polymorphonuclear Leukocytes: Implications for Tatâ€Mediated Pathogenesis. Journal of Infectious Diseases, 2000, 182, 1643-1651.	1.9	70
190	Inhibition of CXCR4-Dependent HIV-1 Infection by Extracellular HIV-1 Tat. Biochemical and Biophysical Research Communications, 2000, 270, 992-996.	1.0	83
191	Kaposi's Sarcoma Cells of Different Etiologic Origins Respond to HIV-Tat through the Flk-1/KDR (VEGFR-2): Relevance in AIDS-KS Pathology. Biochemical and Biophysical Research Communications, 2000, 273, 267-271.	1.0	32
192	Inhibition of Angiogenesis and Vascular Tumor Growth by Interferon-Producing Cells. American Journal of Pathology, 2000, 156, 1381-1393.	1.9	117
193	Vascular Endothelial Growth Factor-C Stimulates the Migration and Proliferation of Kaposi's Sarcoma Cells. Journal of Biological Chemistry, 1999, 274, 27617-27622.	1.6	86
194	Tumor invasion: molecular shears blunted by green tea. Nature Medicine, 1999, 5, 1216-1216.	15.2	164
195	Potentiation of the malignant phenotype of the undifferentiated ARO thyroid cell line by insertion of thebcl-2 gene. , 1999, 81, 956-962.		13
196	Thrombospondin-1 inhibits Kaposi's sarcoma (KS) cell and HIV-1 Tat-induced angiogenesis and is poorly expressed in KS lesions. , 1999, 188, 76-81.		44
197	Motility Induced by Human Immunodeficiency Virus-1 Tat on Kaposi's Sarcoma Cells Requires Platelet-Activating Factor Synthesis. American Journal of Pathology, 1999, 155, 1731-1739.	1.9	30
198	Anti-KS activity still a mystery. Nature Medicine, 1998, 4, 748-748.	15.2	2

#	Article	IF	Citations
199	TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. , 1998, 75, 246-253.		231
200	Tumor and endothelial cell invasion of basement membranes. Pathology and Oncology Research, 1998, 4, 230-241.	0.9	166
201	Identification of a Novel Domain of HIV Tat Involved in Monocyte Chemotaxis. Journal of Biological Chemistry, 1998, 273, 15895-15900.	1.6	108
202	Monocyte-derived dendritic cells and monocytes migrate to HIV-Tat RGD and basic peptides. Aids, 1998, 12, 261-268.	1.0	48
203	Transferrin Promotes Endothelial Cell Migration and Invasion: Implication in Cartilage Neovascularization. Journal of Cell Biology, 1997, 136, 1375-1384.	2.3	134
204	The Î²-core fragment of human chorionic gonadotrophin inhibits growth of KaposiÊ¼s sarcoma-derived cells and a new immortalized KaposiÊ¼s sarcoma cell line. Aids, 1997, 11, 713-721.	1.0	101
205	Interaction of HIV-1 Tat Protein with Heparin. Journal of Biological Chemistry, 1997, 272, 11313-11320.	1.6	179
206	Urokinase-Type Plasminogen Activator Overexpression Enhances the Invasive Capacity of Endothelial Cells. Microvascular Research, 1997, 53, 254-260.	1.1	17
207	Suppression of invasive behavior of melanoma cells by stable expression of anti-sense perlecan cDNA. Annals of Oncology, 1997, 8, 1257-1261.	0.6	59
208	The cAMP analog 8-Cl-cAMP inhibits growth and induces differentiation and apoptosis in retinoblastoma cells. , 1997, 72, 1088-1094.		25
209	Isolation of spindle-shaped cell populations from primary cultures of Kaposi's sarcoma of different stage. Cancer Letters, 1996, 100, 125-132.	3.2	21
210	Promotion of tumour metastases and induction of angiogenesis by native HIV-1 Tat protein from BK virus/tat transgenic mice. Aids, 1996, 10, 701-710.	1.0	42
211	Over-expression of hepatocyte growth factor in human Kaposi's sarcoma. , 1996, 65, 168-172.		36
212	Synergism betweenN-acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models. , 1996, 67, 842-848.		51
213	The angiogenesis induced by HIVâ€“1 Tat protein is mediated by the Flkâ€“1/KDR receptor on vascular endothelial cells. Nature Medicine, 1996, 2, 1371-1375.	15.2	363
214	Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells byN-acetylcysteine. International Journal of Cancer, 1995, 61, 121-129.	2.3	118
215	Invasive phenotype of MCF10A cells overexpressing câ€Haâ€•ras and câ€•erb Bâ€2 oncogenes. International Journal of Cancer, 1995, 63, 815-822.	2.3	76
216	Chemopreventive properties and mechanisms ofN-acetylcysteine. The experimental background. Journal of Cellular Biochemistry, 1995, 59, 33-41.	1.2	114

#	Article	IF	Citations
217	A Single Cis-acting Element in a Short Promoter Segment of the Gene Encoding the Interphotoreceptor Retinoid-binding Protein Confers Tissue-specific Expression. Journal of Biological Chemistry, 1995, 270, 1289-1294.	1.6	49
218	Effect of osteoblast supernatants on cancer cell migration and invasion. Cancer Letters, 1995, 97, 69-74.	3.2	21
219	The Î±3Î²1 Integrin Is Involved in Melanoma Cell Migration and Invasion. Experimental Cell Research, 1995, 219, 233-242.	1.2	126
220	HIV-1 tat Acts as a Growth Factor and Induces Angiogenic Activity in BK Virus/tat Transgenic Mice. Antibiotics and Chemotherapy, 1994, 46, 88-101.	0.5	7
221	Retinoic acid negatively regulates Î²4 integrin expression and suppresses the malignant phenotype in a Lewis lung carcinoma cell line. Clinical and Experimental Metastasis, 1994, 12, 63-72.	1.7	15
222	Angiogenic potential in vivo by KaposiÊ¼s sarcoma cell-free supernatants and HIV-1 tat product: inhibition of KS-like lesions by tissue inhibitor of metalloproteinase-2. Aids, 1994, 8, 1237-1244.	1.0	147
223	Alteration of Laminin Production in Small-Cell Lung Carcinoma: Possible Correlation with the Absence of the Basement Membrane. Tumor Biology, 1993, 14, 279-287.	0.8	4
224	Inhibition of Malignant Tumor Cell Invasion: An Approach to Anti-Progression. , 1993, 61, 335-350.		4
225	Matrigel promotes retinoblastoma cell growthin vitro andin vivo. International Journal of Cancer, 1992, 52, 234-240.	2.3	46
226	Propagation and properties of KaposiÊ¼s sarcoma-derived cell lines obtained from patients with AIDS: similarity of cultured cells to smooth muscle cells. Aids, 1991, 5, 1485-1493.	1.0	22
227	Hypomethylation of the interphotoreceptor retinoid-binding protein (IRBP) promoter and first exon is linked to expression of the gene. Nucleic Acids Research, 1990, 18, 5181-5187.	6.5	23
228	Thein vitro invasiveness and interactions with laminin of K-1735 melanoma cells. Evidence for different laminin-binding affinities in high and low metastatic variants. Clinical and Experimental Metastasis, 1989, 7, 437-451.	1.7	36
229	mRNA for interphotoreceptor retinoid-binding protein (IRBP): Distribution and size diversity in vertebrate species. Experimental Eye Research, 1989, 49, 171-180.	1.2	20
230	Decline of Fibroblast Chemotaxis with Age of Donor and Cell Passage Number. Collagen and Related Research, 1988, 8, 23-37.	2.2	41
231	High Chemotactic Motility and Growth in Hard Agar of a Variant of RSV-Transformed Fibroblasts are Lost in Late Passages. Tumori, 1988, 74, 1-6.	0.6	2
232	â€œIn Vitroâ€•Models for Studying the Malignant Phenotype: Chemotaxis and Chemoinvasion. Advances in Experimental Medicine and Biology, 1988, 233, 215-226.	0.8	4
233	Dermatofibrosarcoma Protuberans: Altered Collagen Metabolism in Cell Culture. Journal of Investigative Dermatology, 1985, 85, 381-384.	0.3	12
234	Fibroblast Chemotaxis. Collagen and Related Research, 1985, 5, 283-296.	2.2	43

#	Article	IF	Citations
235	Comparison of the Chemotactic Response to Conditioned Medium of Balb/c3T3 Fibroblasts and their SV 40 Transformants. Tumori, 1985, 71, 97-100.	0.6	8
236	A method to select cell populations with enhanced chemotatic activity. Bioscience Reports, 1984, 4, 311-318.	1.1	7
237	Enhanced chemotaxis of tumor-derived and virus-transformed cells to fibronectin and fibroblast-conditioned medium. International Journal of Cancer, 1984, 33, 43-48.	2.3	61
238	Human Chorionic Gonadotropin Inhibits Kaposiâ€™s Sarcoma Associated Angiogenesis, Matrix Metalloprotease Activity, and Tumor Growth. , 0, .		8
239	Overcoming Resistance to Checkpoint Inhibitors: Natural Killer Cells in Non-Small Cell Lung Cancer. Frontiers in Oncology, 0, 12, .	1.3	12